Evidence map›Paper›PMID 42730897›Full record

ArticleBioresources and bioprocessing2026

Antibiotic- and inducer-free biosynthesis of indican from crude glycerol using engineered probiotic Escherichia coli Nissle 1917.

Li-Jing Mao, Jia-Qi Su, Yu-Lan Mo, Jing Wang, Fu-Cheng He, Min Xiong, Yong-Jun Liu, Feng-Qing Wang, Liang-Bin Xiong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Li-Jing Mao *Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Jia-Qi Su *Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Yu-Lan Mo *Department of General Surgery, Jinshan Central Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Shanghai, 201599, People's Republic of China.
Jing Wang *Guilin Layn Natural Ingredients Crop, Guiling, 541100, People's Republic of China.
Fu-Cheng HeDepartment of General Surgery, Jinshan Central Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Shanghai, 201599, People's Republic of China.
Min XiongCollege of Marine and Biology Engineering, Yancheng Institute of Technology, Yancheng, 224051, Jiangsu, People's Republic of China.
Yong-Jun LiuGuilin Layn Natural Ingredients Crop, Guiling, 541100, People's Republic of China. liu.yongjun@layn.com.cn.
Feng-Qing WangState Key Laboratory of Bioreactor Engineering, Newworld Institute of Biotechnology, East China University of Science and Technology, Shanghai, 200237, People's Republic of China.
Liang-Bin XiongDepartment of General Surgery, Jinshan Central Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Shanghai, 201599, People's Republic of China. xionglb@sumhs.edu.cn.ORCID http://orcid.org/0000-0002-7335-6724

Funding

Academic Mentorship for Scientific Research Cadre Project AMSCP-24-01National Key Research and Development Program of China 2022YFA0912200National Natural Science Foundation of China 32100067Scientific Research and Cultivation Fund of Jiangwan Hospital, Hongkou District, Shanghai JWKY2026-03
6 · The paper itself

Abstract

Chemical synthesis of indigo relies on aniline and formaldehyde feedstocks, inevitably generating carcinogenic byproducts and imposing severe environmental burdens, driving the urgent demand for sustainable bio-manufacturing alternatives. As a water-soluble glycoside precursor of indigo, indican circumvents the cytotoxicity and product accumulation issues caused by hydrophobic indigo precipitation, emerging as an ideal intermediate for green indigo production. Herein, we developed an antibiotic- and inducer-free biosynthesis platform using the probiotic Escherichia coli Nissle 1917 (EcN). By harnessing its native high-copy plasmids, constitutive expression of the flavin-containing monooxygenase FMO

Indexed as

Antibiotic-free productionEndogenous plasmid engineeringEscherichia coli Nissle 1917IndicanIndigoPtUGT

Identifiers

PMID42730897
PMCPMC13570848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.